MX2019002925A - Modulacion inmune con agonistas de tlr9 para el tratamiento del cancer. - Google Patents
Modulacion inmune con agonistas de tlr9 para el tratamiento del cancer.Info
- Publication number
- MX2019002925A MX2019002925A MX2019002925A MX2019002925A MX2019002925A MX 2019002925 A MX2019002925 A MX 2019002925A MX 2019002925 A MX2019002925 A MX 2019002925A MX 2019002925 A MX2019002925 A MX 2019002925A MX 2019002925 A MX2019002925 A MX 2019002925A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer treatment
- immune modulation
- tlr9 agonists
- tlr9
- agonists
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title 1
- 230000008102 immune modulation Effects 0.000 title 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 abstract 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 abstract 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 abstract 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 abstract 1
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662394845P | 2016-09-15 | 2016-09-15 | |
| US201762486738P | 2017-04-18 | 2017-04-18 | |
| PCT/US2017/051742 WO2018053242A1 (en) | 2016-09-15 | 2017-09-15 | Immune modulation with tlr9 agonists for cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019002925A true MX2019002925A (es) | 2019-09-05 |
Family
ID=61620152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019002925A MX2019002925A (es) | 2016-09-15 | 2017-09-15 | Modulacion inmune con agonistas de tlr9 para el tratamiento del cancer. |
Country Status (10)
| Country | Link |
|---|---|
| US (6) | US10463686B2 (enExample) |
| EP (1) | EP3512499A4 (enExample) |
| JP (2) | JP7200093B2 (enExample) |
| KR (1) | KR20190096936A (enExample) |
| CN (1) | CN110114057A (enExample) |
| AU (1) | AU2017325981A1 (enExample) |
| CA (1) | CA3036978A1 (enExample) |
| IL (2) | IL292658A (enExample) |
| MX (1) | MX2019002925A (enExample) |
| WO (1) | WO2018053242A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015013673A1 (en) | 2013-07-25 | 2015-01-29 | Aurasense Therapeutics, Llc | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
| WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
| WO2018053242A1 (en) | 2016-09-15 | 2018-03-22 | Idera Pharmaceuticals, Inc. | Immune modulation with tlr9 agonists for cancer treatment |
| CA3037380A1 (en) | 2016-10-11 | 2018-04-19 | Agenus Inc. | Anti-lag-3 antibodies and methods of use thereof |
| TW202402800A (zh) | 2017-05-01 | 2024-01-16 | 美商艾吉納斯公司 | 抗ｔｉｇｉｔ抗體類和使用彼等之方法 |
| WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
| MX2019013648A (es) | 2017-05-19 | 2021-01-08 | Wuxi Biologics Shanghai Co Ltd | Anticuerpos monoclonales novedosos para proteina 4 asociada con el linfocito t citotoxico (ctla-4). |
| US20210340544A1 (en) * | 2018-10-18 | 2021-11-04 | Idera Pharmaceuticals, Inc. | Tlr9 modulators for treating cancer |
| CA3113895A1 (en) * | 2018-11-01 | 2020-05-07 | Faron Pharmaceuticals Oy | Tlr9 agonists for use in downregulating clever-1 expression on alternatively activated macrophages |
| BR112021012631A2 (pt) | 2018-12-26 | 2021-12-14 | Xilio Dev Inc | Anticorpos anti-ctla4 e métodos de uso dos mesmos |
| CN115697389A (zh) * | 2020-03-09 | 2023-02-03 | 戴纳瓦克斯技术公司 | 针对破伤风、白喉和百日咳的主动加强免疫 |
| CN116406276A (zh) * | 2020-09-22 | 2023-07-07 | 特萨乐斯生命科学公司 | 使用toll样受体激动剂的癌症疗法 |
| AR125753A1 (es) | 2021-05-04 | 2023-08-09 | Agenus Inc | Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001012804A2 (en) | 1999-08-13 | 2001-02-22 | Hybridon, Inc. | MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES |
| US20040214783A1 (en) | 2002-05-08 | 2004-10-28 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
| US20030129251A1 (en) | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
| AU2002231336B2 (en) | 2000-12-27 | 2007-06-28 | Surefire Medical, Inc. D/B/A Trisalus Life Sciences | Immunomodulatory polynucleotides and methods of using the same |
| US7276489B2 (en) | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
| US8158768B2 (en) | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
| PT1575977E (pt) * | 2002-12-23 | 2009-12-15 | Dynavax Tech Corp | Oligonucleótidos de sequência imunoestimuladora e métodos de utilização dos mesmos |
| EP2371834B1 (en) | 2003-06-11 | 2016-02-17 | Idera Pharmaceuticals, Inc. | Stabilized immunomodulatory oligonucleotides |
| CN100482673C (zh) | 2003-07-15 | 2009-04-29 | 艾德拉药物股份有限公司 | 使用免疫刺激性寡核苷酸和/或免疫子化合物结合细胞因子和/或化疗剂或放射治疗对免疫系统的协同刺激作用 |
| KR101126030B1 (ko) | 2003-07-15 | 2012-03-19 | 이데라 파마슈티칼즈, 인코포레이티드 | 사이토킨 및/또는 화학치료제 또는 방사선 치료와 연계하여면역자극 올리고누클레오티드 및/또는 이뮤노머 화합물을이용하여 면역계를 공동 상승 자극시키는 방법 |
| US7427405B2 (en) | 2004-06-15 | 2008-09-23 | Idera Pharmaceuticals, Inc. | Immunostimulatory oligonucleotide multimers |
| HUE036894T2 (hu) | 2004-06-15 | 2018-08-28 | Idera Pharmaceuticals Inc | Immunstimuláló oligonukleotid multimerek |
| CN101268101A (zh) | 2005-07-07 | 2008-09-17 | 科利制药集团公司 | 用于癌症治疗的抗-CTLA-4抗体和含有CpG基序的合成寡脱氧核苷酸联合治疗 |
| WO2007052058A1 (en) | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics Srl | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
| US7470674B2 (en) | 2005-11-07 | 2008-12-30 | Idera Pharmaceuticals, Inc. | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
| CA2632940A1 (en) | 2005-12-20 | 2007-07-05 | Idera Pharmaceuticals, Inc. | Immunostimulatory activity of palindromic immune modulatory oligonucleotides (imo tm) contiaining different lengths of palindromic segments |
| US20080031887A1 (en) | 2006-06-30 | 2008-02-07 | Joseph Lustgarten | Conjugates for inducing targeted immune responses and methods of making and using same |
| WO2008073959A2 (en) | 2006-12-12 | 2008-06-19 | Idera Pharmaceuticals, Inc. | Synthetic agonists of tlr9 |
| CA2693266C (en) | 2007-08-01 | 2015-06-30 | Idera Pharmaceuticals, Inc. | Novel synthetic agonists of tlr9 |
| BRPI1008063A2 (pt) | 2009-01-30 | 2015-08-25 | Idera Pharmaceuticals Inc | Agonistas sinteticas de tlr9 |
| EP2533779A4 (en) | 2010-02-09 | 2013-08-21 | Georgia Health Sciences University Res Inst Inc | ALPHA-METHYL-TRYPTOPHANE AS INHIBITORS OF INDOLEAMINE DIOXYGENASE |
| KR102315754B1 (ko) | 2010-05-14 | 2021-10-22 | 더 제너럴 하스피톨 코포레이션 | 종양 특이적 신생항원을 확인하는 조성물 및 방법 |
| FR2975600B1 (fr) * | 2011-05-24 | 2013-07-05 | Assist Publ Hopitaux De Paris | Agents pour le traitement de tumeurs |
| JP2014527983A (ja) * | 2011-09-19 | 2014-10-23 | ザ ジョンズ ホプキンス ユニバーシティー | 癌免疫療法 |
| CN105163754B (zh) | 2012-09-20 | 2018-01-05 | 王荣福 | 前列腺特异性肿瘤抗原及其用途 |
| JP6508785B2 (ja) | 2013-10-25 | 2019-05-08 | ファーマサイクリックス エルエルシー | ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置 |
| KR20160093012A (ko) | 2013-11-05 | 2016-08-05 | 코그네이트 바이오서비시즈, 인코포레이티드 | 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물 |
| WO2016030863A1 (en) * | 2014-08-29 | 2016-03-03 | Glaxosmithkline Intellectual Property Development Limited | Compounds and methods for treating viral infections |
| MX391478B (es) | 2014-10-10 | 2025-03-21 | Idera Pharmaceuticals Inc | Composiciones de agonista de tlr9 e inhibidores de punto de control para usarse en la respuesta inmune contra el cáncer. |
| WO2016128542A1 (en) | 2015-02-13 | 2016-08-18 | Transgene Sa | Immunotherapeutic vaccine and antibody combination therapy |
| ES2987696T3 (es) | 2015-05-29 | 2024-11-15 | Dynavax Tech Corp | Agonista polinucleotídico del receptor de tipo toll 9 para el tratamiento del cáncer de pulmón |
| MX2017015308A (es) | 2015-05-29 | 2018-07-06 | Merck Sharp & Dohme | Combinacion de un antagonista de pd-1 y un oligonucleotido tipo cpg-c para tratar cancer. |
| WO2018053242A1 (en) | 2016-09-15 | 2018-03-22 | Idera Pharmaceuticals, Inc. | Immune modulation with tlr9 agonists for cancer treatment |
-
2017
- 2017-09-15 WO PCT/US2017/051742 patent/WO2018053242A1/en not_active Ceased
- 2017-09-15 US US15/705,631 patent/US10463686B2/en not_active Expired - Fee Related
- 2017-09-15 EP EP17851589.6A patent/EP3512499A4/en not_active Withdrawn
- 2017-09-15 KR KR1020197010562A patent/KR20190096936A/ko not_active Ceased
- 2017-09-15 JP JP2019514720A patent/JP7200093B2/ja active Active
- 2017-09-15 IL IL292658A patent/IL292658A/en unknown
- 2017-09-15 CN CN201780067972.4A patent/CN110114057A/zh active Pending
- 2017-09-15 MX MX2019002925A patent/MX2019002925A/es unknown
- 2017-09-15 CA CA3036978A patent/CA3036978A1/en active Pending
- 2017-09-15 AU AU2017325981A patent/AU2017325981A1/en not_active Abandoned
-
2019
- 2019-03-14 IL IL265370A patent/IL265370B/en unknown
- 2019-08-30 US US16/557,597 patent/US10835550B2/en not_active Expired - Fee Related
- 2019-08-30 US US16/557,630 patent/US10772907B2/en not_active Expired - Fee Related
-
2020
- 2020-09-14 US US17/020,355 patent/US20210052625A1/en not_active Abandoned
- 2020-10-21 US US17/076,677 patent/US11224611B2/en active Active
-
2021
- 2021-10-18 JP JP2021170043A patent/JP2022009200A/ja active Pending
- 2021-12-06 US US17/543,341 patent/US20220088054A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL292658A (en) | 2022-07-01 |
| EP3512499A1 (en) | 2019-07-24 |
| JP2019529415A (ja) | 2019-10-17 |
| US20200054663A1 (en) | 2020-02-20 |
| US20200138848A1 (en) | 2020-05-07 |
| IL265370B (en) | 2022-06-01 |
| US10835550B2 (en) | 2020-11-17 |
| CA3036978A1 (en) | 2018-03-22 |
| CN110114057A (zh) | 2019-08-09 |
| US10463686B2 (en) | 2019-11-05 |
| US20180125877A1 (en) | 2018-05-10 |
| WO2018053242A1 (en) | 2018-03-22 |
| US10772907B2 (en) | 2020-09-15 |
| EP3512499A4 (en) | 2020-08-05 |
| US20210038630A1 (en) | 2021-02-11 |
| US20220088054A1 (en) | 2022-03-24 |
| US11224611B2 (en) | 2022-01-18 |
| KR20190096936A (ko) | 2019-08-20 |
| IL265370A (en) | 2019-05-30 |
| JP7200093B2 (ja) | 2023-01-06 |
| AU2017325981A1 (en) | 2019-04-11 |
| US20210052625A1 (en) | 2021-02-25 |
| JP2022009200A (ja) | 2022-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019002925A (es) | Modulacion inmune con agonistas de tlr9 para el tratamiento del cancer. | |
| MX2018008427A (es) | Combinaciones anti-cd20 para tratar tumores. | |
| EA201591674A1 (ru) | Противораковые вакцины и способы лечения с их применением | |
| MX2018008426A (es) | Combinaciones anti-egfr para tratar tumores. | |
| MX393818B (es) | Terapias de combinación para el tratamiento de cáncer. | |
| ZA201802966B (en) | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment | |
| MX2019011858A (es) | Metodos para tratar el cancer con anticuerpos dirigidos a ps con agentes inmunooncologicos. | |
| TW201611847A (en) | Compounds and compositions for treating EGFR expressing tumors | |
| MX2022008868A (es) | Tratamiento del cancer con tg02. | |
| PH12017550063A1 (en) | Combination therapies for treating cancers | |
| MX2016002273A (es) | Tratamiento de cancer con una combinacion de un antagonista de proteina de muerte programada 1 y dinaciclib. | |
| MX2020011772A (es) | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. | |
| MA39817A (fr) | Thérapie combinatoires comprenant des agents anti-angiogenèse et des agonistes se liant à ox40 | |
| MX382902B (es) | Inhibidor de la vía noth en combinación con un agente inmunoterapéutico para usarse en el tratamiento de cáncer. | |
| MX2020003770A (es) | Terapias de combinacion para tratar cancer. | |
| CO2019000753A2 (es) | Métodos para tratar el cáncer de próstata | |
| EA201991818A1 (ru) | Лечение рака | |
| EA201890868A1 (ru) | Бактерии с ослабленной вирулентностью для лечения злокачественных солидных опухолей | |
| JO3541B1 (ar) | علاجات طبية قائمة على اناموريلين | |
| NZ754522A (en) | Oxabicycloheptanes for modulation of immune response | |
| MX2020002585A (es) | Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer. | |
| MX2019008233A (es) | Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral. | |
| MX2021002884A (es) | Terapia de combinacion para el tratamiento de cancer de prostata. | |
| MX2019014489A (es) | Programa de dosificacion para tesetaxel y capecitabina. | |
| EA201990411A1 (ru) | Способы лечения рака предстательной железы |